Greenwich LifeSciences’ $26.4 Million Common Stock Offering

Sichenzia Ross Ference LLP represented Aegis Capital Corp in the offering while Sheppard Mullin advised Greenwich LifeSciences, Inc. on the deal.

Greenwich LifeSciences, Inc. (NASDAQ: GSLI) executed its offering of 660,000 shares of the common stock, sold to the public at a price of $40.00 per share for gross proceeds of approximately $26,400,000. This offering was made pursuant to a registration statement on Form S-1 (File No. 333-251366) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and subsequently declared effective on December 17, 2020 and a registration statement on Form S-1 (File No. 333-251438) previously filed with the SEC and immediately declared effective on December 17, 2020.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

The Sichenzia Ross Ference LLP team advising Aegis Capital Corp., as a sole bookrunner, was led by Partners Gregory Sichenzia (Picture), Darrin Ocasio, Avital Perlman, and Jeff Cahlon, and Associate Yian Pan.

The Sheppard Mullin deal team was led by partner Jeff Fessler and associate Nazia Khan.

Involved fees earner: Jeffrey Fessler – Sheppard Mullin; Nazia Khan – Sheppard Mullin; Jeffrey Cahlon – Sichenzia Ross Ference LLP; Darrin Ocasio – Sichenzia Ross Ference LLP; Yian Pan – Sichenzia Ross Ference LLP; Avital Perlman – Sichenzia Ross Ference LLP; Gregory Sichenzia – Sichenzia Ross Ference LLP;

Law Firms: Sheppard Mullin; Sichenzia Ross Ference LLP;

Clients: Aegis Capital Corporation; Greenwich LifeSciences;


Author: Ambrogio Visconti